Upcoming Reports [full schedule to be confirmed]

Schedule of Publications 2025

2025

Oct

  • Multiple Sclerosis

    Corporate Reputation of Pharma 2024/25

  • Neurodegenerative Edition

    Corporate Reputation of Pharma 2024/25

  • Neurology Edition

    Corporate Reputation of Pharma 2024/25

Sep

  • Rare Diseases Edition

    Corporate Reputation of Pharma 2024/25

  • Diabetes Edition

    Corporate Reputation of Pharma 2024/25

  • Bleeding Disorders Edition

    Corporate Reputation of Pharma 2024/25

Aug

  • China Edition

    Corporate Reputation of Pharma 2024/25

  • Japan Edition

    Corporate Reputation of Pharma 2024/25

  • ANZ Edition

    Corporate Reputation of Pharma 2024/25

  • Italy Edition

    Corporate Reputation of Pharma 2024/25

Jul

  • Spain Edition

    Corporate Reputation of Pharma 2024/25

  • Germany Edition

    Corporate Reputation of Pharma 2024/25

  • France Edition

    Corporate Reputation of Pharma 2024/25

    Published

Jun

  • Cancer: Prostate Cancer Edition

    Corporate Reputation of Pharma 2024/25

    Published

  • Cancer: Lung Cancer Edition

    Corporate Reputation of Pharma 2024/25

    Published

  • Cancer: Blood Cancer Edition

    Corporate Reputation of Pharma 2024/25

    Published

  • Cancer: Breast Cancer Edition

    Corporate Reputation of Pharma 2024/25

    Published

  • Cancer: All Cancers Edition

    Corporate Reputation of Pharma 2024/25

    Published

May

  • Canada Edition

    Corporate Reputation of Pharma 2024/25

    Published

  • UK Edition

    Corporate Reputation of Pharma 2024/25

    Published

  • USA Edition

    Corporate Reputation of Pharma 2024/25

    Published

Apr

  • Global Edition

    Corporate Reputation of Pharma 2024/25

    Published

Feb

  • Environmental, Social & Governance Report 2024

    Pharma and ESG

    Published

2024

Nov

  • Neurodegenerative Edition

    Corporate Reputation of Pharma 2023/24

    Published

  • Multiple Sclerosis Edition

    Corporate Reputation of Pharma 2023/24

    Published

  • Neurology Edition

    Corporate Reputation of Pharma 2023/24

    Published

Oct

  • Cardiovascular Edition

    Corporate Reputation of Pharma 2023/24

    Published

  • Patients in Action – Tackling the Healthcare Crisis

    Patients in Action

    Published

  • Mental Health Edition

    Corporate Reputation of Pharma 2023/24

    Published

Sep

  • Asia Edition

    Corporate Reputation of Pharma 2023/24

    Published

Aug

  • Bleeding Disorders Edition

    Corporate Reputation of Pharma 2023/24

    Published

  • Rare Diseases Edition

    Corporate Reputation of Pharma 2023/24

    Published

Jul

  • Spain Edition

    Corporate Reputation of Pharma 2023/24

    Published

  • France Edition

    Corporate Reputation of Pharma 2023/24

    Published

  • Italy Edition

    Corporate Reputation of Pharma 2023/24

    Published

Jun

  • Germany Edition

    Corporate Reputation of Pharma 2023/24

    Published

  • Cancer Edition II

    Corporate Reputation of Pharma 2022

    Published

  • Cancer Edition I

    Corporate Reputation of Pharma 2023/24

    Published

May

  • Canada Edition

    Corporate Reputation of Pharma 2023/24

    Published

  • UK Edition

    Corporate Reputation of Pharma 2023/24

    Published

  • USA Edition

    Corporate Reputation of Pharma 2023/24

    Published

Apr

  • Global Edition

    Corporate Reputation of Pharma 2023/24

    Published

2023

Dec

  • Environmental, Social & Governance Report

    New Survey 2023

    Published

Nov

  • Launch of 2023-2024 survey

    New Survey 2023

    Published

Oct

  • Neurological Edition [with Multiple Sclerosis]

    Corporate Reputation of Pharma 2022

    Published

Sep

  • Arthritis Edition

    Corporate Reputation of Pharma 2022

    Published

  • Mental Health Edition

    Corporate Reputation of Pharma 2022

    Published

  • Spain Edition

    Corporate Reputation of Pharma 2022

    Published

Aug

  • Ukraine Report

    New Survey 2023

    Published

  • Rare Diseases Edition [with Bleeding Disorders]

    Corporate Reputation of Pharma 2022

    Published

  • Australia, New Zealand, China and Japan Edition

    Corporate Reputation of Pharma 2022

    Published

Jul

  • Respiratory Edition

    Corporate Reputation of Pharma 2022, Respiratory Edition

    Published

  • France Edition

    Corporate Reputation of Pharma 2022

    Published

Jun

  • Italy Edition

    Corporate Reputation of Pharma 2022

    Published

  • Germany Edition

    Corporate Reputation of Pharma 2022

    Published

  • Cancer Edition

    Corporate Reputation of Pharma 2022

    Published

May

  • Canada Edition

    Corporate Reputation of Pharma 2022

    Published

  • UK Edition

    Corporate Reputation of Pharma 2022

    Published

  • USA Edition

    Corporate Reputation of Pharma 2022

    Published

Apr

  • Global Edition

    Corporate Reputation of Pharma 2022

    Published

Up